FabI (enoyl-acyl carrier protein reductase): a key target for the development of antibacterial agents

Antimicrobial resistance (AMR) is currently a serious threat to human health. Consequently, the development of new antibacterial agents targeting underexplored bacterial pathways and thereby circumventing existing resistance mechanisms is urgent. The widely conserved bacterial type II fatty acid synthesis (FAS-II) pathway represents an attractive target to tackle antimicrobial resistance. FAS-II is mediated by a series of Fab enzymes. Among these, enoyl-acyl carrier protein reductase (ENR) catalyzes the reduction of a double bond in enoyl-ACP to acyl-ACP, a crucial step in bacterial fatty acid biosynthesis. In humans, fatty acid biosynthesis occurs via a distinct multi-enzyme FAS-I complex, making FAS-II enzymes promising targets for the development of new antibacterial agents. FabI is the most extensively characterized ENR and is widely distributed among clinically relevant bacterial pathogens. Besides FabI, alternative ENRs, including FabK, FabL, FabV, and the mycobacterial homolog InhA, have been identified in different microorganisms. FabI represents a validated antibacterial target, with several covalent and non-covalent FabI inhibitors having emerged as potential antibiotics. Among these, advanced clinical candidates such as afabicin and nilofabicin have demonstrated the therapeutic potential of ENR inhibition. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes.

Authors

Institutions

Publication Details

Journal
Frontiers in Drug Discovery
Published
2026-11-18
DOI
https://doi.org/10.3389/fddsv.2026.1947040
Primary Topic
Microbial Natural Products and Biosynthesis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FabI (enoyl-acyl carrier protein reductase): a key target for the development of antibacterial agents

Gabriel Corrêa Veríssimo, Raquel Goes de Castro, Débora Maria Abrantes Costa, Mateus Sá Magalhães Serafim et al.
Frontiers in Drug Discovery
Microbial Natural Products and Biosynthesis
article

FabI (enoyl-acyl carrier protein reductase): a key target for the development of antibacterial agents

Gabriel Corrêa Veríssimo, Raquel Goes de Castro, Débora Maria Abrantes Costa, Mateus Sá Magalhães Serafim, Fernanda Kelly Marcelino e Oliveira
article en

Abstract

Antimicrobial resistance (AMR) is currently a serious threat to human health. Consequently, the development of new antibacterial agents targeting underexplored bacterial pathways and thereby circumventing existing resistance mechanisms is urgent. The widely conserved bacterial type II fatty acid synthesis (FAS-II) pathway represents an attractive target to tackle antimicrobial resistance. FAS-II is mediated by a series of Fab enzymes. Among these, enoyl-acyl carrier protein reductase (ENR) catalyzes the reduction of a double bond in enoyl-ACP to acyl-ACP, a crucial step in bacterial fatty acid biosynthesis. In humans, fatty acid biosynthesis occurs via a distinct multi-enzyme FAS-I complex, making FAS-II enzymes promising targets for the development of new antibacterial agents. FabI is the most extensively characterized ENR and is widely distributed among clinically relevant bacterial pathogens. Besides FabI, alternative ENRs, including FabK, FabL, FabV, and the mycobacterial homolog InhA, have been identified in different microorganisms. FabI represents a validated antibacterial target, with several covalent and non-covalent FabI inhibitors having emerged as potential antibiotics. Among these, advanced clinical candidates such as afabicin and nilofabicin have demonstrated the therapeutic potential of ENR inhibition. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes.

Frontiers in Drug DiscoveryVol. 6
Universidade Federal de Minas Gerais (BR)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Universidade Federal de Minas Gerais
Good health and well-being
Microbial Natural Products and Biosynthesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon